Our approach is aimed at preventing pain complications and having patients return to normalcy. Our primary area of focus is endometriosis-related pain in adult women. Chiima Therapeutics is currently investigating its lead compound CHM-001 for non-hormonal treatment for moderate to severe endometriosis-related pain in adult women. This compound has demonstrated disease modifying effects of endometriosis. We are a first-in-class new molecular entity. Our pre-clinical data in this compound has demonstrated positive Proof of Concept and efficacy data. CHM-001 compound has begun IND- enabling studies.